Evidence map›Paper›PMID 18816412›Full record

ArticleBMC microbiology2008

Bordetella pertussis isolates in Finland: serotype and fimbrial expression.

Eriikka Heikkinen, Dorothy K Xing, Rose-Marie Olander, Jukka Hytönen, Matti K Viljanen, Jussi Mertsola, Qiushui He

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in BMC microbiology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03197597 (EUpertstrain 4 Study of Bordetella Pertussis Isolates), which is not on this map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
1.4field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03197597 completednot on this mapstarted 2015, after this paper: background citation

EUpertstrain 4 Study of Bordetella Pertussis Isolates

TypeobservationalSponsorUniversity of TurkuRan2015 to 2016Enrolled265ConditionsBordetella Pertussis, Whooping CoughArmsStrain isolation from the nasopharynx
3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 36 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Evolution ofEuro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2021
    Article
  8. Review
  9. Pertactin-deficientEuro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2019
    Article
  10. Population dynamics and antigenic drift ofEmerging microbes & infections · 2019
    Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 3 countries.

Eriikka HeikkinenPertussis Reference Laboratory, National Public Health Institute, Kiinamyllynkatu 13, 20520 Turku, Finland. Eriikka.Heikkinen@ktl.fi
Dorothy K Xing
Rose-Marie Olander
Jukka Hytönen
Matti K Viljanen
Jussi Mertsola
Qiushui He
University of Turku · FIInstitute for Molecular Medicine Finland · FINational Institute for Biological Standards and Control · GBPublic Health Institute · USTurku University Hospital · FI

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundBordetella pertussis causes whooping cough or pertussis in humans. It produces several virulence factors, of which the fimbriae are considered adhesins and elicit immune responses in the host. B. pertussis has three distinct serotypes Fim2, Fim3 or Fim2,3. Generally, B. pertussis Fim2 strains predominate in unvaccinated populations, whereas Fim3 strains are often isolated in vaccinated populations. In Finland, pertussis vaccination was introduced in 1952. The whole-cell vaccine contained two strains, 18530 (Fim3) since 1962 and strain 1772 (Fim2,3) added in 1976. After that the vaccine has remained the same until 2005 when the whole-cell vaccine was replaced by the acellular vaccine containing pertussis toxin and filamentous hemagglutinin. Our aims were to study serotypes of Finnish B. pertussis isolates from 1974 to 2006 in a population with > 90% vaccination coverage and fimbrial expression of the isolates during infection. Serotyping was done by agglutination and serotype-specific antibody responses were determined by blocking ELISA.

resultsAltogether, 1,109 isolates were serotyped. Before 1976, serotype distributions of Fim2, Fim3 and Fim2,3 were 67%, 19% and 10%, respectively. From 1976 to 1998, 94% of the isolates were Fim2 serotype. Since 1999, the frequency of Fim3 strains started to increase and reached 83% during a nationwide epidemic in 2003. A significant increase in level of serum IgG antibodies against purified fimbriae was observed between paired sera of 37 patients. The patients infected by Fim3 strains had antibodies which blocked the binding of monoclonal antibodies to Fim3 but not to Fim2. Moreover, about one third of the Fim2 strain infected patients developed antibodies capable of blocking of binding of both anti-Fim2 and Fim3 monoclonal antibodies.

conclusionDespite extensive vaccinations in Finland, B. pertussis Fim2 strains were the most common serotype. Emergence of Fim3 strains started in 1999 and coincided with nationwide epidemics. Results of serotype-specific antibody responses suggest that Fim2 strains could express Fim3 during infection, showing a difference in fimbrial expression between in vivo and in vitro.

Indexed as

AdolescentAdultAntibodies, BacterialBordetella pertussisChildChild, PreschoolFemaleFimbriae ProteinsFinlandGene ExpressionHumansImmunoglobulin GInfantMaleMiddle AgedSerotypingAntibodies, BacterialFimbriae ProteinsImmunoglobulin G

Identifiers

PMID18816412
PMCPMC2562373
OpenAlexW2114831023

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.